Neurology

Biogen Appoints Daniel Quirk, MD, as Chief Medical OfficerBiogen Appoints Daniel Quirk, MD, as Chief Medical Officer

Biogen Appoints Daniel Quirk, MD, as Chief Medical Officer

CAMBRIDGE, Mass., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) has appointed Daniel Quirk, M.D., M.P.H., M.B.A. as…

7 months ago
Plus Therapeutics Showcases Leptomeningeal Metastases Programs at the 2024 SNO Annual Meeting in Houston, TexasPlus Therapeutics Showcases Leptomeningeal Metastases Programs at the 2024 SNO Annual Meeting in Houston, Texas

Plus Therapeutics Showcases Leptomeningeal Metastases Programs at the 2024 SNO Annual Meeting in Houston, Texas

Company will present results from the ReSPECT-LM Phase 1 clinical trial of Rhenium (186Re) Obisbemeda for leptomeningeal metastases (LM) and…

7 months ago
Axsome Therapeutics Presents Data from Multiple Programs Spanning Its Innovative Neuroscience Portfolio at Psych Congress 2024Axsome Therapeutics Presents Data from Multiple Programs Spanning Its Innovative Neuroscience Portfolio at Psych Congress 2024

Axsome Therapeutics Presents Data from Multiple Programs Spanning Its Innovative Neuroscience Portfolio at Psych Congress 2024

NEW YORK, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel…

7 months ago
JACC: Cardiovascular Interventions Publishes Peer-Reviewed Article on Emerging Hybrid Intracoronary Imaging TechnologiesJACC: Cardiovascular Interventions Publishes Peer-Reviewed Article on Emerging Hybrid Intracoronary Imaging Technologies

JACC: Cardiovascular Interventions Publishes Peer-Reviewed Article on Emerging Hybrid Intracoronary Imaging Technologies

– Conavi Medical’s Novasight Hybrid™ System is the first technology to combine both IVUS and OCT to enable simultaneous and…

7 months ago
ACG Presidential Plenary to Highlight Analysis of Xifaxan(R) (rifaximin) Risk Reduction of Overt Hepatic Encephalopathy (OHE) RecurrenceACG Presidential Plenary to Highlight Analysis of Xifaxan(R) (rifaximin) Risk Reduction of Overt Hepatic Encephalopathy (OHE) Recurrence

ACG Presidential Plenary to Highlight Analysis of Xifaxan(R) (rifaximin) Risk Reduction of Overt Hepatic Encephalopathy (OHE) Recurrence

Additional ACG presentation to focus on impact of Xifaxan on OHE rehospitalizationsLAVAL, QC / ACCESSWIRE / October 27, 2024 /…

7 months ago
Laurel Bridge Software Joins ‘Radiology Reimagined’ Demonstration at RSNA 2024Laurel Bridge Software Joins ‘Radiology Reimagined’ Demonstration at RSNA 2024

Laurel Bridge Software Joins ‘Radiology Reimagined’ Demonstration at RSNA 2024

Collaborative effort highlights the possibilities of integration of AI into radiology workflowNEWARK, DE / ACCESSWIRE / October 25, 2024 /…

7 months ago
Evotec and Bristol Myers Squibb Expand Proteomics PartnershipEvotec and Bristol Myers Squibb Expand Proteomics Partnership

Evotec and Bristol Myers Squibb Expand Proteomics Partnership

Key scientific achievements drive the expansion of the pipeline of molecular glue degraders in fields beyond oncologyEvotec receives a US$…

7 months ago
AmplifyMD Wins 2024 Rising Star Digital Health Hub AwardAmplifyMD Wins 2024 Rising Star Digital Health Hub Award

AmplifyMD Wins 2024 Rising Star Digital Health Hub Award

Virtual care innovator honored by Digital Health Hub Foundation for Health Equity LOS GATOS, Calif., Oct. 22, 2024 /PRNewswire/ --…

7 months ago
QHSLab, Inc. Welcomes Dr. Juan D. Oms, MD, FAPA, as Medical Advisor for Psychiatry and Behavioral HealthQHSLab, Inc. Welcomes Dr. Juan D. Oms, MD, FAPA, as Medical Advisor for Psychiatry and Behavioral Health

QHSLab, Inc. Welcomes Dr. Juan D. Oms, MD, FAPA, as Medical Advisor for Psychiatry and Behavioral Health

WEST PALM BEACH, FL, Oct. 22, 2024 (GLOBE NEWSWIRE) -- QHSLab, Inc. (the "Company") (OTCQB: USAQ), a leader in digital…

7 months ago
Grifols Partners with BARDA for Proof-of-Concept Testing of Ocular Immunoglobulin as Treatment for Sulfur Mustard-Induced Eye InjuryGrifols Partners with BARDA for Proof-of-Concept Testing of Ocular Immunoglobulin as Treatment for Sulfur Mustard-Induced Eye Injury

Grifols Partners with BARDA for Proof-of-Concept Testing of Ocular Immunoglobulin as Treatment for Sulfur Mustard-Induced Eye Injury

Initiative will test Grifols ocular surface immunoglobulin (OSIG) eye drops to evaluate their nonclinical efficacy in neutralizing symptoms from exposure…

7 months ago